ArticleJournal of inflammation research2025
Refractory Gout and Metabolic Syndrome in a Chinese Cohort: A Propensity Score Matching and Nonlinear Relationship Analysis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The coexistence of refractory gout and metabolic syndrome may worsen patient prognosis, but the association and the nonlinear relationships with clinical parameters have not been fully elucidated. This study aimed to explore this association and reveal its potential nonlinear patterns in a Chinese cohort. Methods: This retrospective study included clinical data from 4111 gout patients from a single center in Tianjin, China between 2014 and 20234. Based on international standards, patients were divided into the refractory gout group (n=1972) and the non-refractory gout group (n=2139). Metabolic syndrome was defined according to the NCEP-ATP III criteria. Propensity score matching (1:1) was used to control for confounding factors, and multivariable logistic regression and restricted cubic spline models were employed to assess the associations and nonlinear relationships. Results: After propensity score matching, the prevalence of metabolic syndrome was significantly higher in the refractory gout group compared to the non-refractory gout group (52.5% vs 15.8%, P<0.001). Multivariable analysis showed that metabolic syndrome was the strongest independent factor associated with refractory gout (adjusted OR=9.689, 95% CI: 5.727-16.392, P<0.001). Restricted cubic spline analysis revealed nonlinear relationships between clinical parameters and disease risk: age showed a rising and then falling trend with metabolic syndrome risk peaking around 58 years; ESR exhibited a bell-shaped relationship with both conditions; CRP showed a positive nonlinear relationship with refractory gout; SBP had a U-shaped relationship with refractory gout. Blood glucose levels were significantly associated with refractory gout, particularly in patients with tophi and longer disease duration. Conclusion: Metabolic syndrome prevalence is significantly higher in refractory gout, and metabolic burden shows complex nonlinear relationships with clinical parameters. Managing metabolic risk requires special attention in younger patients, those with a long disease duration, and those with high uric acid levels, which are critical for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.